Gastric Cancer PDX Models

With many new agents under development, including targeted therapies for gastric cancer, there is a need for predictive research models such as patient-derived xenografts (PDX) for preclinical evaluation. PDX models are proven to be highly predictive models for preclinical drug assessment. The CrownBio collection contains over 100 well characterized gastric cancer PDX models, including EGFR amplified models and cachexic models. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER CANCER SUBTYPE # per page
GA0006 ADCCLICK TO VIEW
GA0019 ADCCLICK TO VIEW
GA0022 ADCCLICK TO VIEW
GA0023 ADCCLICK TO VIEW
GA0025 Signet-ring cell carcinomaCLICK TO VIEW
GA0031 ADCCLICK TO VIEW
GA0033 ADCCLICK TO VIEW
GA0037 ADCCLICK TO VIEW
GA0044 ADCCLICK TO VIEW
GA0046 ADCCLICK TO VIEW
GA0055 ADCCLICK TO VIEW
GA0060 ADCCLICK TO VIEW
GA0074 ADCCLICK TO VIEW
GA0075 ADCCLICK TO VIEW
GA0080 ADCCLICK TO VIEW
GA0087 NEC, carcinoidCLICK TO VIEW
GA0091 NEC, carcinoidCLICK TO VIEW
GA0095 ADCCLICK TO VIEW
GA0098 ADCCLICK TO VIEW
GA0103 ADCCLICK TO VIEW